Value of calprotectin S100 A8/A9 in predicting the severity of Mycoplasma pneumoniae pneumonia in children

ZHOU Pei; PENG Li; XU Lu; LIU Qing-Hua; HUANG Han; ZHONG Li-Li

doi:10.7499/j.issn.1008-8830.2401076

PDF(615 KB)

Chinese Journal of Contemporary Pediatrics ›› 2024, Vol. 26 ›› Issue (7) : 716-722. DOI: 10.7499/j.issn.1008-8830.2401076

CLINICAL RESEARCH

Value of calprotectin S100 A8/A9 in predicting the severity of Mycoplasma pneumoniae pneumonia in children

ZHOU Pei, PENG Li, XU Lu, LIU Qing-Hua, HUANG Han, ZHONG Li-Li

Author information +

History +

Abstract

Objective To investigate the role of calprotectin S100 A8/A9 complex in evaluating the condition of children with severe Mycoplasma pneumoniae pneumonia (SMPP). Methods A prospective study was conducted among 136 children with Mycoplasma pneumoniae pneumonia (MPP) and 30 healthy controls. According to the severity of the condition, the children with MPP were divided into mild subgroup (40 children) and SMPP subgroup (96 children). The levels of S100 A8/A9 complex and related inflammatory factors were compared between the MPP group and the healthy control group, as well as between the two subgroups of MPP. The role of S100 A8/A9 in assessing the severity of MPP was explored. Results The MPP group had a significantly higher level of S100 A8/A9 than the healthy control group, with a significantly greater increase in the SMPP subgroup (P<0.05). The multivariate logistic regression analysis showed that the increases in serum C reactive protein (CRP) and S100A8/A9 were closely associated with SMPP (P<0.05). The receiver operating characteristic (ROC) curve analysis showed that the combined measurement of serum S100 A8/A9 and CRP had an area under the ROC curve of 0.904 in predicting SMPP, which was significantly higher than the AUC of S100 A8/A9 or CRP alone (P<0.05), with a specificity of 0.718 and a sensitivity of 0.952. Conclusions S100 A8/A9 is closely associated with the severity of MPP, and the combination of S100 A8/A9 with CRP is more advantageous for assessing the severity of MPP in children.

Key words

Mycoplasma pneumoniae pneumonia / Calprotectin S100 A8/A9 / C reactive protein / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

ZHOU Pei, PENG Li, XU Lu, LIU Qing-Hua, HUANG Han, ZHONG Li-Li. Value of calprotectin S100 A8/A9 in predicting the severity of Mycoplasma pneumoniae pneumonia in children[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(7): 716-722 https://doi.org/10.7499/j.issn.1008-8830.2401076

References

1 Gao LW, Yin J, Hu YH, et al. The epidemiology of paediatric Mycoplasma pneumoniae pneumonia in North China: 2006 to 2016[J]. Epidemiol Infect, 2019, 147: e192. PMID: 31364532. PMCID: PMC6518602. DOI: 10.1017/S0950268819000839.
2 Yang J, Hooper WC, Phillips DJ, et al. Cytokines in Mycoplasma pneumoniae infections[J]. Cytokine Growth Factor Rev, 2004, 15(2-3): 157-168. PMID: 15110799. DOI: 10.1016/j.cytogfr.2004.01.001.
3 Sreejit G, Flynn MC, Patil M, et al. S100 family proteins in inflammation and beyond[J]. Adv Clin Chem, 2020, 98: 173-231. PMID: 32564786. DOI: 10.1016/bs.acc.2020.02.006.
4 Hidalgo A, Libby P, Soehnlein O, et al. Neutrophil extracellular traps: from physiology to pathology[J]. Cardiovasc Res, 2022, 118(13): 2737-2753. PMID: 34648022. PMCID: PMC9586562. DOI: 10.1093/cvr/cvab329.
5 马开树, 刘成坤, 屈开新, 等. 血清S100A8/A9与社区获得性肺炎患者严重程度及预后关联的回顾性队列研究[J]. 临床肺科杂志, 2022, 27(12): 1850-1856. DOI: 10.3969/j.issn.1009-6663.2022.12.014.
6 Havelka A, Sejersen K, Venge P, et al. Calprotectin, a new biomarker for diagnosis of acute respiratory infections[J]. Sci Rep, 2020, 10(1): 4208. PMID: 32144345. PMCID: PMC7060262. DOI: 10.1038/s41598-020-61094-z.
7 Xie S, Wang J, Tuo W, et al. Serum level of S100A8/A9 as a biomarker for establishing the diagnosis and severity of community-acquired pneumonia in children[J]. Front Cell Infect Microbiol, 2023, 13: 1139556. PMID: 37180431. PMCID: PMC10172663. DOI: 10.3389/fcimb.2023.1139556.
8 国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南（2023年版）[J]. 传染病信息, 2023, 36(4): 291-297. DOI: 10.3969/j.issn.1007-8134.2023.04.002.
9 Liu B, Chang X, Yan N. Clinical analysis of the epidemiology and changes in inflammatory indexes of Mycoplasma pneumonia in acute and recovery stage pediatric patients[J]. Transl Pediatr, 2022, 11(10): 1645-1655. PMID: 36345443. PMCID: PMC9636459. DOI: 10.21037/tp-22-416.
10 Otheo E, Rodríguez M, Moraleda C, et al. Viruses and Mycoplasma pneumoniae are the main etiological agents of community-acquired pneumonia in hospitalized pediatric patients in Spain[J]. Pediatr Pulmonol, 2022, 57(1): 253-263. PMID: 34633153. DOI: 10.1002/ppul.25721.
11 Tong L, Huang S, Zheng C, et al. Refractory Mycoplasma pneumoniae pneumonia in children: early recognition and management[J]. J Clin Med, 2022, 11(10): 2824. PMID: 35628949. PMCID: PMC9144103. DOI: 10.3390/jcm11102824.
12 Zhu Y, Luo Y, Li L, et al. Immune response plays a role in Mycoplasma pneumoniae pneumonia[J]. Front Immunol, 2023, 14: 1189647. PMID: 37304280. PMCID: PMC10250694. DOI: 10.3389/fimmu.2023.1189647.
13 Huang X, Li D, Liu F, et al. Clinical significance of D-dimer levels in refractory Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2021, 21(1): 14. PMID: 33407216. PMCID: PMC7787414. DOI: 10.1186/s12879-020-05700-5.
14 Yang M, Meng F, Gao M, et al. Cytokine signatures associate with disease severity in children with Mycoplasma pneumoniae pneumonia[J]. Sci Rep, 2019, 9(1): 17853. PMID: 31780733. PMCID: PMC6882793. DOI: 10.1038/s41598-019-54313-9.
15 邹映雪. 肺炎支原体肺炎炎症指标异常的临床意义[J]. 中华实用儿科临床杂志, 2021, 36(16): 1209-1214. DOI: 10.3760/cma.j.cn101070-20210725-00879.
16 Zhou Y, Hu M, Ye B, et al. Early prediction of necrotizing pneumonia from Mycoplasma pneumoniae pneumonia with large pulmonary lesions in children[J]. Sci Rep, 2020, 10(1): 19061. PMID: 33149220. PMCID: PMC7643079. DOI: 10.1038/s41598-020-76083-5.
17 张芙荣, 周卫芳, 李玉琴, 等. 中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值在重症肺炎支原体肺炎中的诊断价值[J]. 中华实用儿科临床杂志, 2022, 37(4): 260-264. DOI: 10.3760/cma.j.cn101070-20201013-01612.
18 牛艳华, 孙超, 王超, 等. 重症肺炎支原体肺炎患儿的危险因素分析[J]. 上海医学, 2023, 46(6): 388-392. DOI: 10.19842/j.cnki.issn.0253-9934.2023.06.006.
19 Fang C, Mao Y, Jiang M, et al. Pediatric Critical Illness Score, clinical characteristics and comprehensive treatment of children with severe Mycoplasma pneumoniae pneumonia[J]. Front Surg, 2022, 9: 897550. PMID: 35693303. PMCID: PMC9174934. DOI: 10.3389/fsurg.2022.897550.
20 Lee KL, Lee CM, Yang TL, et al. Severe Mycoplasma pneumoniae pneumonia requiring intensive care in children, 2010-2019[J]. J Formos Med Assoc, 2021, 120(1 Pt 1): 281-291. PMID: 32948415. DOI: 10.1016/j.jfma.2020.08.018.
21 Guo S, Mao X, Liang M. The moderate predictive value of serial serum CRP and PCT levels for the prognosis of hospitalized community-acquired pneumonia[J]. Respir Res, 2018, 19(1): 193. PMID: 30285748. PMCID: PMC6167901. DOI: 10.1186/s12931-018-0877-x.
22 Wang J, Mao J, Chen G, et al. Evaluation on blood coagulation and C-reactive protein level among children with Mycoplasma pneumoniae pneumonia by different chest imaging findings[J]. Medicine (Baltimore), 2021, 100(3): e23926. PMID: 33545964. PMCID: PMC7837868. DOI: 10.1097/MD.0000000000023926.
23 Zhang C, Zhang Q, Du JL, et al. Correlation between the clinical severity, bacterial load, and inflammatory reaction in children with Mycoplasma pneumoniae pneumonia[J]. Curr Med Sci, 2020, 40(5): 822-828. PMID: 33123897. PMCID: PMC7595045. DOI: 10.1007/s11596-020-2261-6.
24 乔红梅, 庞焕香, 张云峰, 等. 肺炎支原体肺炎患儿IL-6、IL-10、TNF-α的变化[J]. 临床儿科杂志, 2012, 30(1): 59-61. DOI: 10.3969/j.issn.1000-3606.2012.01.015.
25 Fernandes CD, Arriaga MB, Costa MCM, et al. Host inflammatory biomarkers of disease severity in pediatric community-acquired pneumonia: a systematic review and meta-analysis[J]. Open Forum Infect Dis, 2019, 6(12): ofz520. PMID: 31867405. PMCID: PMC6917028. DOI: 10.1093/ofid/ofz520.
26 李娟, 颜维孝, 马如海. 重症MPP患儿外周血Th1/Th2类细胞因子变化及对近期预后不良的预测分析[J]. 中国免疫学杂志, 2023, 39(10): 2222-2226. DOI: 10.3969/j.issn.1000-484X.2023.10.036.
27 Tian F, Chen LP, Yuan G, et al. Differences of TNF-α, IL-6 and gal-3 in lobar pneumonia and bronchial pneumonia caused by Mycoplasma pneumoniae[J]. Technol Health Care, 2020, 28(6): 711-719. PMID: 32200365. DOI: 10.3233/THC-192011.
28 Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance[J]. Eur J Immunol, 2010, 40(7): 1830-1835. PMID: 20583029. DOI: 10.1002/eji.201040391.
29 Jin X, Zhu Y, Zhang Y, et al. Assessment of levels of D-dimer and interferon-γ in pediatric patients with Mycoplasma pneumoniae pneumonia and its clinical implication[J]. Exp Ther Med, 2018, 16(6): 5025-5030. PMID: 30546408. PMCID: PMC6256836. DOI: 10.3892/etm.2018.6873.
30 Bai S, Wang W, Ye L, et al. IL-17 stimulates neutrophils to release S100A8/A9 to promote lung epithelial cell apoptosis in Mycoplasma pneumoniae-induced pneumonia in children[J]. Biomed Pharmacother, 2021, 143: 112184. PMID: 34562768. DOI: 10.1016/j.biopha.2021.112184.